Piramal Enterprises Ltd.’s Pharma Solutions business is investing ~CAD$25 million to expand its Aurora facility in Canada with the addition of a new state-of-the-art wing dedicated to manufacturing Active Pharmaceutical Ingredients (APIs).

The Piramal Pharma Solutions’ (PPS) Aurora facility will enhance its offerings with the addition of ~10,500 sq.-ft. of new manufacturing space that will support the facility’s ability to provide APIs and HPAPIs down to an Occupational Exposure Limit (OEL) of 1mcg/m3. It will also include filtration and drying capabilities that will enhance service offerings at the facility.

Peter DeYoung,  chief executive officer, Piramal Pharma Solutions said, “We are delighted to announce the capacity expansion at our Aurora facility in Canada. This additional capacity will help us to strengthen our presence in Canada as well as service other geographies such as North America and Europe, whilst enabling us to support our customer’s API requirements and market demand for integrated solutions. As a Patient Centric organization, Piramal Pharma Solutions is committed to serving the patient community and reducing the burden of disease.”

The expansion will also include two new reactor suites as well as a dedicated filter dryer room and a portable filter dryer. The expansion is expected to be completed and running by April 30, 2021. The Aurora facility has successful inspections by the US FDA, the UK MHRA and the PMDA.